➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
McKesson
Medtronic
Moodys

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

DOXYCYCLINE HYCLATE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Doxycycline Hyclate patents expire, and what generic alternatives are available?

Doxycycline Hyclate is a drug marketed by Pliva, Medicis, Actavis Labs Fl Inc, Ajanta Pharma Ltd, Alembic Pharms Ltd, Amneal Pharms, Changzhou Pharm, Chartwell Life Sci, Halsey, Heather, Hikma Intl Pharms, Interpharm, Mutual Pharm, Mylan, Par Pharm, Pvt Form, Ranbaxy, Sun Pharm Industries, Superpharm, Warner Chilcott, Watson Labs, Zhejiang Yongtai, Zydus Pharms, West-ward Pharms Int, Actavis Elizabeth, Heritage Pharms Inc, Impax Labs Inc, Mylan Pharms Inc, Prinston Inc, Amneal Pharms Co, Apotex, Cadila, Caribe Holdings, Emcure Pharms Ltd, Epic Pharma Llc, Heritage Pharma, Lannett Co Inc, Larken Labs, Lupin Ltd, Mayne Pharma Inc, Novel Labs Inc, Oaklock Llc, and Vintage Pharms. and is included in sixty-four NDAs.

The generic ingredient in DOXYCYCLINE HYCLATE is doxycycline hyclate. There are twenty-eight drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the doxycycline hyclate profile page.

US ANDA Litigation and Generic Entry Outlook for Doxycycline Hyclate

A generic version of DOXYCYCLINE HYCLATE was approved as doxycycline hyclate by CARIBE HOLDINGS on November 8th, 1982.

  Start Trial

Drug patent expirations by year for DOXYCYCLINE HYCLATE
Drug Prices for DOXYCYCLINE HYCLATE

See drug prices for DOXYCYCLINE HYCLATE

Drug Sales Revenue Trends for DOXYCYCLINE HYCLATE

See drug sales revenues for DOXYCYCLINE HYCLATE

Recent Clinical Trials for DOXYCYCLINE HYCLATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Galderma R&DPhase 4
Royal Alexandra HospitalPhase 2
University of AlbertaPhase 2

See all DOXYCYCLINE HYCLATE clinical trials

Pharmacology for DOXYCYCLINE HYCLATE
Paragraph IV (Patent) Challenges for DOXYCYCLINE HYCLATE
Tradename Dosage Ingredient NDA Submissiondate
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2017-09-28
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2017-09-28
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-11-05
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-11-05
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-07-01
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2015-07-01
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2014-05-19
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2014-05-19
DORYX TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2008-12-19
DORYX MPC TABLET, DELAYED RELEASE;ORAL doxycycline hyclate 050795 2008-12-19

US Patents and Regulatory Information for DOXYCYCLINE HYCLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ajanta Pharma Ltd DOXYCYCLINE HYCLATE doxycycline hyclate TABLET;ORAL 211584-001 Jun 1, 2020 AB RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm Industries DOXYCYCLINE HYCLATE doxycycline hyclate TABLET;ORAL 065134-001 May 13, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Watson Labs DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 061717-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Ranbaxy DOXYCYCLINE HYCLATE doxycycline hyclate CAPSULE;ORAL 062479-002 Dec 23, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Epic Pharma Llc DOXYCYCLINE HYCLATE doxycycline hyclate TABLET;ORAL 065182-001 May 13, 2005 AB RX No No   Start Trial   Start Trial   Start Trial
Actavis Elizabeth DOXYCYCLINE HYCLATE doxycycline hyclate TABLET, DELAYED RELEASE;ORAL 090134-003 May 22, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Mallinckrodt
McKesson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.